8 completed, 2 terminated. 4 Phase 1, 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Quantum Genomics SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH) Firibastat (QGC001) Period 1 - Hypertension (HTN) | Phase 3 | Terminated | Quantum Genomics SA | 419 | 2021-08-05 | 2023-01-17 |
| Firibastat in Treatment-resistant Hypertension Firibastat, Placebo - Hypertension | Phase 3 | Completed | Quantum Genomics SA | 515 | 2020-06-25 | 2022-10-20 |
| Pharmacokinetics in End Stage Renal Disease Patients firibastat - Healthy Volunteers, Renal Failure | Phase 1 | Completed | Quantum Genomics SA | 28 | 2019-09-17 | 2021-03-10 |
| Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction Ramipril, Firibastat - Myocardial Infarction | Phase 2 | Completed | Quantum Genomics SA | 295 | 2019-06-04 | 2023-02-27 |
| Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations Firibastat - Healthy Males | Phase 1 | Completed | Quantum Genomics SA | 12 | 2019-02-15 | 2019-06-18 |
| Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins QGC001 - Hypertension | Phase 2 | Completed | Quantum Genomics SA | 256 | 2017-10-13 | 2018-12-11 |
| QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF QGC001, Placebo - Heart Failure | Phase 2 | Terminated | Quantum Genomics SA | 23 | 2016-06-01 | 2018-10-16 |
| Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension QGC001, Placebo - Essential Hypertension | Phase 2 | Completed | Quantum Genomics SA | 34 | 2015-01-01 | 2016-09-28 |
| Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)], Placebo - Essential Hypertension | Phase 1 | Completed | Quantum Genomics SA | 69 | 2012-12-01 | 2013-07-16 |
| Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)], Placebo - Essential Hypertension | Phase 1 | Completed | Quantum Genomics SA | 56 | 2012-02-01 | 2013-07-16 |
Essential Hypertension (3) · Hypertension (3) · Heart Failure (1) · Myocardial Infarction (1) · Renal Insufficiency (1)
firibastat (5) · Ramipril (1)
France (7) · Germany (3) · Poland (3) · United Kingdom (3) · United States (3) · Czechia (2) · Hungary (2) · Spain (2) · Canada (1) · Netherlands (1) · Norway (1) · Slovakia (1)
Faiez Zannad, MD (1) · George Bakris, MD (1) · Gilles Montalescot, MD, PhD (1) · Keith C. Ferdinand, MD FACC (1)
PMID 33027067, PMID 30882604, PMID 31014072, PMID 31923435, PMID 36757536
2018 (1), 2019 (1)